Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
March 12, 2026American Journal of HematologyOpen Access

Epidemiology of Cancer‐Associated Venous Thromboembolism Across the United States

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Prior epidemiological studies on cancer-associated venous thromboembolism were limited by homogenous patient populations.

Population

1 628 626 US patients with a new cancer diagnosis between 2018 and 2023

Design

Electronic health record-based retrospective cohort study

Follow-up

12 months

Key result

The cumulative incidence of venous thromboembolism at 6 months was 2.7% and at 12 months was 3.7% in patients with a new cancer diagnosis.

Authors

BLBarbara D. LamJRJustine RyuOJOmid Jafari

Discussion

Loading...

Member takes

Overview

Prompts vigilance for VTE after new cancer diagnosis; confirms independent association with increased mortality.

Key Points

  • This research aims to evaluate the epidemiology of cancer-associated venous thromboembolism (VTE) in a diverse US population.
  • Utilized the Cosmos dataset of Epic electronic health records comprised of US patients from all 50 states.
  • Included patients diagnosed with cancer between 2018 and 2023.
  • Computed cumulative incidence of VTE at 6 and 12 months post-diagnosis.
  • Employed Cox regression to identify risk factors and assess the impact of VTE type on mortality.
  • Identified 1,628,626 patients with cumulative incidence of VTE at 2.7% at 6 months and 3.7% at 12 months.
  • Major risk factors included prior VTE, cancer type, advanced disease stage, and chemotherapy.
  • VTE occurrence in the first year was linked to higher mortality rates.

Structured PICO

P
Population
1,628,626 patients in the United States with a new cancer diagnosis between 2018 and 2023, representative of the US census in terms of age, race, ethnicity, and insurance coverage.
O
Outcome
Cumulative incidence of venous thromboembolism (VTE) at 6 and 12 months after the cancer diagnosis datehard clinical

In a large, nationally representative US cohort of over 1.6 million patients, the 1-year cumulative incidence of cancer-associated VTE was 3.7% and was independently associated with increased mortality.

Cite This Study

Lam et al. (2026) studied this question. The cumulative incidence of venous thromboembolism at 6 months was 2.7% and at 12 months was 3.7% in patients with a new cancer diagnosis.

synapsesocial.com/papers/69b258a396eeacc4fcec876bhttps://doi.org/10.1002/ajh.70271
View Full Paper
Ask AI
Bookmark
Share